stockportfolio.pro logostockportfolio.pro
Stocks Screener Start 7-day free trial
Stocks / REGN / Revenue

Regeneron Pharmaceuticals, Inc. Revenue 2008–2025

Regeneron Pharmaceuticals, Inc. (REGN) annual revenue by fiscal year, computed from SEC filings. Compound growth +27.3%/yr over 17 years.

Fiscal yearRevenueChange (YoY)
FY 2025$14.34B+1.0%
FY 2024$14.20B+8.3%
FY 2023$13.12B+7.8%
FY 2022$12.17B-24.3%
FY 2021$16.07B+89.1%
FY 2020$8.50B+29.6%
FY 2019$6.56B+27.4%
FY 2018$5.15B-12.4%
FY 2017$5.87B+20.8%
FY 2016$4.86B+18.4%
FY 2015$4.10B+45.5%
FY 2014$2.82B+34.0%
FY 2013$2.10B+52.7%
FY 2012$1.38B+209.2%
FY 2011$445.82M-2.9%
FY 2010$459.07M+21.0%
FY 2009$379.27M+59.1%
FY 2008$238.46M

Source: Regeneron Pharmaceuticals, Inc. SEC filings — income statement (10-K). Refreshed nightly.

See the full picture for Regeneron Pharmaceuticals, Inc.

Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.

Open the interactive view — free

Regeneron Pharmaceuticals, Inc. — frequently asked questions

What is Regeneron Pharmaceuticals, Inc.'s revenue?

Regeneron Pharmaceuticals, Inc. (REGN) reported revenue of $14.34B for fiscal year 2025, per its SEC filings.

How has Regeneron Pharmaceuticals, Inc.'s revenue changed over time?

Between fiscal 2008 and 2025, REGN's revenue grew at roughly 27.3% per year (compound annual rate), from $238.46M to $14.34B.

Where does this data come from?

Figures are computed from Regeneron Pharmaceuticals, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.

More REGN financial history

Full REGN fundamentals page → · All 1,500+ companies →